Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.86 |
| ▸ | GAA | P10253 | 6/20 | 0.86 |
| ▸ | NPC1 | O15118 | 5/20 | 0.86 |
| ▸ | RAB9A | P51151 | 5/20 | 0.86 |
| ▸ | GLA | P06280 | 4/20 | 0.86 |
| ▸ | APP | P05067 | 12/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.69 |
| ▸ | GFER | P55789 | 2/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.69 |
| ▸ | RELA | Q04206 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995933 | 0.93 | MAPT (1.00) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL29939237 | 0.92 | MAPT (0.79) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL31319825 | 0.92 | MAPT (0.79) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL27001616 | 0.92 | MAPT (0.79) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL6854930 | 0.91 | MAPT (0.96) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL5593469 | 0.90 | MAPT (0.69) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL15496408 | 0.89 | MAPT (0.79) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL13853339 | 0.89 | APP (1.00) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL13853342 | 0.87 | APP (1.00) | MAPTKDM4EGAANPC1RAB9A | |
| SCHEMBL13853343 | 0.87 | APP (1.00) | MAPTKDM4EGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9833458-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833458-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-05 | — | — | US | disclosed |
| US-20150190400-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150190400-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-07-09 | — | — | US | disclosed |
| US-20120095235-A1 | THIOFLAVIN DERIVATES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH -- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-04-19 | — | — | US | disclosed |
| US-20120095235-A1 | THIOFLAVIN DERIVATES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH -- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-04-19 | — | — | US | disclosed |
| US-20080154042-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH | 2008-06-26 | — | — | US | disclosed |
| US-20080154042-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH | 2008-06-26 | — | — | US | disclosed |
| US-7351401-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition | UNIVERSITY OF PITTSBURGH (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351401-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition | UNIVERSITY OF PITTSBURGH (US) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095235-A1 | THIOFLAVIN DERIVATES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, MAPT, PSEN2 | MAPT 2/4885KDM4E 3866/4885GAA 1020/4885 |
| US-20080154042-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | MAPT 3/4885KDM4E 4234/4885GAA 986/4885 |
| US-20150190400-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | MAPT 3/4885KDM4E 4438/4885GAA 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.